ViaNautis Welcomes Ray Jupp as Their New Chief Scientific Officer
ViaNautis Bio, a leading name in biotechnology focused on innovative genetic therapies, has announced a significant addition to their executive team—Dr. Ray Jupp is now the Chief Scientific Officer (CSO). His appointment is effective immediately, and he is expected to drive the scientific strategy and research initiatives within the company.
Advancing the polyNaut® Platform
With Dr. Jupp at the helm of scientific operations, ViaNautis aims to further enhance its cutting-edge polyNaut® platform. This unique technology has been designed to tackle the pressing challenges associated with genetic nanomedicine delivery, particularly in the treatment of central nervous system (CNS) diseases. Dr. Jupp's extensive background in the biotech sector positions him well to lead the charge in expanding the pipeline of therapies that the company offers.
Dr. Ray Jupp's Background
Dr. Jupp boasts over 25 years of diverse experience in both biotechnology and the pharmaceutical industry. He previously held the position of CSO at notable companies including Mestag Therapeutics, Enara Bio, and TRex Bio. His expertise is further amplified by his previous roles at UCB, Roche, and Sanofi, where he successfully navigated more than ten drug compounds into the clinical development phase. Holding a PhD in Biochemistry from Cardiff University and having completed a post-doctoral fellowship at the Scripps Research Institute, Dr. Jupp's academic credentials are impressive.
Comments from Dr. Jupp
Commenting on his new role, Dr. Jupp expressed enthusiasm about the opportunities at ViaNautis. He stated, "Joining ViaNautis presents a unique opportunity to advance the development of the Company’s groundbreaking polyNaut® platform. This technology is poised to create precise and targeted treatments aimed at addressing diseases with significant unmet clinical needs. With confirmed capabilities of crossing the blood-brain barrier more efficiently, I look forward to collaborating with the team to further our research and help patients in need."
Support from Leadership
Dr. Adi Hoess, the Chief Executive Officer of ViaNautis, also weighed in on this development, emphasizing that Dr. Jupp’s proven track record in advancing compounds through clinical stages will be vital as the company seeks to broaden its therapeutic offerings. He stated, "Ray’s extensive experience and leadership will play an integral role in furthering our innovative polymer-based nanovesicles and opening new therapeutic avenues for our developments."
Future Directions for ViaNautis
Founded in 2018, ViaNautis has a core mission to leverage the unique capabilities of its polyNaut® technology. This advanced polymer platform is designed for targeted intracellular delivery, making it highly effective in transporting a range of therapeutic molecules including genetic materials. By enabling the efficient delivery of encapsulated payloads into cell cytoplasm, polyNaut® employs GOTO® technology for intracellular transport, making it a distinct player in the field of non-viral delivery systems.
Setting Itself Apart
One of the standout features of polyNaut® is its ability to efficiently target specific cells and navigate through biological barriers, including the challenging blood-brain barrier. Notably, when modified for CNS applications, polyNaut® nanoparticles have demonstrated exceptional delivery rates to the brain, showcasing their potential in treating neurological conditions.
Collaborative Pathways
Moving forward, ViaNautis is not only focusing on its internal therapy pipeline but also aims to collaborate with leading pharmaceutical and biotech companies. These partnerships will unlock the possibilities of penning promising genetic molecules and exploring new therapies that hold real promise for patients suffering from severe conditions.
Frequently Asked Questions
What is the significance of Dr. Jupp's appointment?
Dr. Jupp brings extensive experience in biotech and pharmaceuticals, vital for ViaNautis's growth in genetic therapies.
What is the polyNaut® platform?
It is an innovative technology developed by ViaNautis for targeted delivery of genetic treatments, particularly effective in CNS diseases.
How does polyNaut® improve drug delivery?
This platform enhances the ability to cross the blood-brain barrier and deliver therapies directly to affected cells.
What collaborations is ViaNautis pursuing?
ViaNautis is looking to partner with top pharmaceutical and biotech firms to expand their research and therapy options.
How long has ViaNautis been operational?
ViaNautis was founded in 2018 as a spin-off from University College London (UCL).
